Nottingham cancer detection company floats on AIM

Oncimmune Holdings, a Nottingham-based early cancer detection company, has been admitted to AIM this morning (18 May), in an IPO that raised £11m at a price of 130p per share.

The company is now worth around £66.3m.

Oncimmune has pioneered the development of autoantibody tests that have the potential to detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types.

Geoffrey Hamilton-Fairley, CEO of Oncimmune said: “This is an important day for Oncimmune. OurEarlyCDT®-Lung test has the potential to detect lung cancer up to four years earlier than other methods and our platform can be widely applied to other cancer types. The funds raised will allow us to expand into new markets, particularly Asia, and continue to develop our platform forother indications.

“We are excited to be joining the AIM market today andwould like to thank our new and existing investors for their support and confidence in our EarlyCDT® platform technology.”

Zeus Capital is the nominated adviser and broker to the company.